Argenx’s Phase 3 Study on Empasiprubart: A Potential Game-Changer for MMN Treatment?

Argenx ((ARGX)) announced an update on their ongoing clinical study.

Argenx is currently conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy. The study aims to assess the efficacy and safety of empasiprubart compared to IVIg in treating adults with Multifocal Motor Neuropathy (MMN), a rare neurological disorder. This study is significant as it could offer a new treatment option for MMN patients.

The study tests two main interventions: empasiprubart, a biological treatment administered via intravenous infusion, and IVIg, another biological treatment also given intravenously. The goal is to determine which treatment is more effective and safer for MMN patients.

The study design is interventional, with participants randomly assigned to different treatment groups. It follows a parallel intervention model with quadruple masking, meaning neither the participants nor the care providers, investigators, or outcomes assessors know who receives which treatment. The primary purpose of the study is treatment-focused.

The study began on December 16, 2024, with its primary completion date yet to be announced. The most recent update was on August 19, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

This clinical update could influence Argenx’s stock performance positively by showcasing potential advancements in MMN treatment. It may also impact investor sentiment, especially if empasiprubart proves to be a viable alternative to IVIg. Competitors in the neurological treatment space will be closely monitoring these developments.

The study is ongoing, with further details available on the ClinicalTrials portal.